Suitability of circulating miRNAs as potential prognostic markers in colorectal cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 23, Issue 12, 2014, Pages 2632-2637

  Ristau, Jonas ^a   Staffa, Jürgen ^a   Schrotz King, Petra ^a   Gigic, Biljana ^a   Makar, Karen W ^b   Hoffmeister, Michael ^a   Brenner, Herrmann ^a   Ulrich, Alexis ^c   Schneider, Martin ^c   Ulrich, Cornelia M ^a   Habermann, Nina ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 106A; MICRORNA 143; MICRORNA 16 2; MICRORNA 17; MICRORNA 18A; MICRORNA 20A; MICRORNA 223; MICRORNA 320A; MICRORNA 92A; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; COHORT ANALYSIS; COLORECTAL CANCER; COLORECTAL SURGERY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MALE; PILOT STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; COLORECTAL TUMOR; GENETICS; MIDDLE AGED; PROGNOSIS;

ADULT; AGED; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; PROGNOSIS;

EID: 84919372146     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-14-0556     Document Type: Review

References (35)

1. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215-33.
2. Mitchell PS, Parkin RK, Kroh E.M., Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008; 105: 10513-8.
3. Calin GA, Croce CM MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857-66.
4. Chen X, Ba Y, Ma L., Cai X, Yin Y, Wang K., et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18: 997-1006.
5. Luo X, Burwinkel B, Tao S., Brenner H. MicroRNA signatures: novel biomarker for colorectal cancer? Cancer Epidemiol Biomarkers Prev 2011; 20: 1272-86.
6. Luo X, Stock C, Burwinkel B., Brenner H. Identification and evaluation of plasma microRNAs for early detection of colorectal cancer. PLoS ONE 2013; 8:e62880.
7. Kosaka N, Iguchi H, Ochiya T. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci 2010; 101: 2087-92.
8. Duffy MJ. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? Clin Chem 2001; 47: 624-30.
9. Tan E, Gouvas N, Nicholls R.J., Ziprin P., Xynos E, Tekkis PP. Diagnostic precision of carcinoembryonic antigen in the detection of recurrence of colorectal cancer. Surg Oncol 2009; 18: 15-24.
10. Turchinovich A, Weiz L, Langheinz A., Burwinkel B. Characterization of extracellular circulating microRNA. Nucleic Acids Res 2011; 39: 7223-33.
11. Huang Z, Huang D, Ni S., Peng Z, Sheng W, Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer 2010; 127: 118-26.
12. Ng EK, Chong WW, Jin H, Lam E.K., Shin VY, Yu J, et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 2009; 58: 1375-81.
13. Zhang GJ, Zhou T, Liu Z.L., Tian HP, Xia SS. Plasma miR-200c and miR-18a as potential biomarkers for the detection of colorectal carcinoma. Mol Clin Oncol 2013; 1: 379-84.
14. Brase JC, Johannes M, Schlomm T., Falth M, Haese A, Steuber T., et al. Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer 2011; 128: 608-16.
15. Pu XX, Huang GL, Guo H.Q., Guo CC, Li H, Ye S, et al Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. J Gastroenterol Hepatol 2010; 25: 1674-80.
16. Boeri M, Verri C, Conte D., Roz L, Modena P, Facchinetti F., et al. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci U S A 2011; 108: 3713-8.
17. Cheng H, Zhang L, Cogdell D.E., Zheng H., Schetter AJ, Nykter M, et al. Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS ONE 2011; 6:e17745.
18. Kroh EM, Parkin RK, Mitchell P.S., Tewari M. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods 2010; 50: 298-301.
19. Wu CW, Ng SS, Dong Y.J., Ng SC, Leung WW, Lee CW, et al Detection of miR-92a and miR-21 in stool samples as potential screening biomarkers for colorectal cancer and polyps. Gut 2012; 61: 739-45.
20. Chen X, Guo X, Zhang H., Xiang Y, Chen J, Yin Y., et al. Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene 2009; 28: 1385-92.
21. Diosdado B, van de Wiel MA, Terhaar Sive Droste JS, Mongera S, Postma C, Meijerink WJ, et al. MiR-17-92 cluster is associated with 13q gain and c-myc expression during colorectal adenoma to ade-nocarcinoma progression. Br J Cancer 2009; 101: 707-14.
22. Earle JS, Luthra R, Romans A., Abraham R, Ensor J, Yao H., et al. Association of microRNA expression with microsatellite instability status in colorectal adenocarcinoma. J Mol Diagn 2010; 12: 433-40.
23. Motoyama K, Inoue H, Takatsuno Y., Tanaka F, Mimori K, Uetake H., et al. Over- and under-expressed microRNAs in human colorectal cancer. Int J Oncol 2009; 34: 1069-75.
24. Schepeler T, Reinert JT, Ostenfeld M.S., Christensen LL, Silahtaroglu AN, Dyrskjot L, et al Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res 2008; 68: 6416-24.
25. Giraldez MD, Lozano JJ, Ramirez G, Hijona E., Bujanda L, Castells A, et al Circulating MicroRNAs as biomarkers of colorectal cancer: results from a genome-wide profiling and validation study. Clin Gas-troenterol Hepatol 2013; 11: 681-8 e3.
26. Brunet A, Pericay C, Moya I., Ferrer A, Dotor E, Pisa A., et al. microRNA expression profile in stage III colorectal cancer: circulating miR-18a and miR-29a as promising biomarkers. Oncol Rep 2013; 30: 320-6.
27. Diaz R, Silva J, Garcia J.M., Lorenzo Y., Garcia V, Pena C, et al Deregulated expression of miR-106a predicts survival in human colon cancer patients. Genes Chromosomes Cancer 2008; 47: 794-802.
28. Schetter AJ, Leung SY, Sohn J.J., Zanetti KA, Bowman ED, Yanaihara N, et al MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008; 299: 425-36.
29. Wang YX, Zhang XY, Zhang B.F., Yang CQ, Chen XM, Gao HJ. Initial study of microRNA expression profiles of colonic cancer without lymph node metastasis. J Dig Dis 2010; 11: 50-4.
30. Chang KH, Miller N, Kheirelseid E.A., Lemetre C., Ball GR, Smith MJ, et al. MicroRNA signature analysis in colorectal cancer: identification of expression profiles in stage II tumors associated with aggressive disease. Int J Colorectal Dis 2011; 26: 1415-22.
31. Kulda V, Pesta M, Topolcan O., Liska V, Treska V, Sutnar A., et al. Relevance of miR-21 and miR-143 expression in tissue samples of colorectal carcinoma and its liver metastases. Cancer Genet Cyto-genet 2010; 200: 154-60.
32. Mosakhani N, Sarhadi VK, Borze I, Karjalainen-Lindsberg ML, Sundstrom J., Ristamaki R, et al. MicroRNA profiling differentiates colorectal cancer according to KRAS status. Genes Chromosomes Cancer 2012; 51: 1-9.
33. Wang CJ, Zhou ZG, Wang L, Yang L., Zhou B, Gu J, et al Clinico-pathological significance of microRNA-31, -143 and -145 expression in colorectal cancer. Dis Markers 2009; 26: 27-34.
34. Kanaan Z, Rai SN, Eichenberger M.R., Roberts H., Keskey B, Pan J, et al Plasma miR-21: a potential diagnostic marker of colorectal cancer. Ann Surg 2012; 256: 544-51.
35. Pritchard CC, Kroh E, Wood B., Arroyo JD, Dougherty KJ, Miyaji MM, et al Blood cell origin of circulating MicroRNAs: a cautionary note for cancer biomarker studies. Cancer Prev Res (Phila) 2012; 5: 492-7.